BCG-022

N/A

Report date: 2024/07/05 14:13:32

Base Information

Drug NameBCG-022
Drug Alias NameBCG-022
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3Anti-Hepatocyte growth factor receptorTubulin polymerisation inhibitors +[6] 
TargetsReceptor tyrosine-protein kinase erbB-3Hepatocyte growth factor receptorTubulin
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co LtdDoma Biopharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDoma Biopharmaceutical (Suzhou) Co LtdBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A